Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

2.

Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.

Palmer CS, Zhan C, Elixhauser A, Halpern MT, Rance L, Feagan BG, Marrie TJ.

Clin Ther. 2000 Feb;22(2):250-64.

PMID:
10743984
3.

A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.

Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.

Curr Med Res Opin. 2008 Mar;24(3):895-906. doi: 10.1185/030079908X273408.

PMID:
18419876
4.

Approaches to drug therapy, formulary, and pathway management in a large community hospital.

Halley HJ.

Am J Health Syst Pharm. 2000 Nov 15;57 Suppl 3:S17-21.

PMID:
11098316
5.

Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.

Clark LC, Davis CW.

Am J Health Syst Pharm. 2000 Nov 15;57 Suppl 3:S10-3.

PMID:
11098314
6.
8.

Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.

Carratalà J, Fernández-Sabé N, Ortega L, Castellsagué X, Rosón B, Dorca J, Fernández-Agüera A, Verdaguer R, Martínez J, Manresa F, Gudiol F.

Ann Intern Med. 2005 Feb 1;142(3):165-72.

PMID:
15684204
9.
10.

Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia.

van der Eerden MM, de Graaff CS, Vlaspolder F, Bronsveld W, Jansen HM, Boersma WG.

Clin Ther. 2004 Feb;26(2):294-303.

PMID:
15038952
12.
13.

Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.

Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D.

Curr Med Res Opin. 2010 Feb;26(2):355-63. doi: 10.1185/03007990903482418.

PMID:
19995325
14.
15.

Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.

Frei CR, Jaso TC, Mortensen EM, Restrepo MI, Raut MK, Oramasionwu CU, Ruiz AD, Makos BR, Ruiz JL, Attridge RT, Mody SH, Fisher A, Schein JR.

Curr Med Res Opin. 2009 Apr;25(4):859-68. doi: 10.1185/03007990902779749 .

PMID:
19231913
16.

Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.

Friedman H, Song X, Crespi S, Navaratnam P.

Value Health. 2009 Nov-Dec;12(8):1135-43. doi: 10.1111/j.1524-4733.2009.00576.x. Epub 2009 Aug 20.

19.

Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.

Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC; MOTIV (MOxifloxacin Treatment IV) Study Group.

Clin Infect Dis. 2008 May 15;46(10):1499-509. doi: 10.1086/587519.

PMID:
18419482
20.

Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.

Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.

Clin Ther. 2008 Feb;30(2):358-71. doi: 10.1016/j.clinthera.2008.01.023.

PMID:
18343274

Supplemental Content

Support Center